Inclusion Criteria:

- adult patients, >/=19 years of age

- metastatic or unresectable colorectal or ovarian cancer refractory to, or unsuitable
for standard therapy

- presence of tumor lesions suitable for DCE-MRI evaluation

- WHO performance status 0-1

- adequate bone marrow, liver and renal function

Exclusion Criteria:

- patient unsuitable for MRI scanning (e.g. metal implants, pacemaker, claustrophobia,
hypersensitivity to DCE-MRI contrast material)

- brain metastases

- clinically significant ascites

- active bleeding, bleeding diathesis, oral anti-vitamin K medication (other than low
dose coumarin) or history of coagulation disorders

- radiation therapy within 3 weeks, or anti-neoplastic therapy <30 days prior to first
dose of study drug

- chronic therapy with systemic steroids or another immunosuppressive agent <2 weeks
prior to first dose of study drug

- treated with bevacizumab in last regimen of systemic therapy